MAPT and early-onset autosomal dominant Alzheimer disease: Of one example, in a phase III trial of bapineuzumab, a humanized anti-Aβ monoclonal antibody, APOEε4 status was associated with differences in both Aβ and tau load in mild-to-moderate Alzheimer’s disease patients.59